Study of AD128 Versus Placebo in Obstructive Sleep Apnea
Status:
Completed
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
Obstructive Sleep Apnea (OSA) is the most common and serious of the sleep disorders.
Long-term, OSA is associated with increased morbidity and mortality, with a number of adverse
cardiovascular, neurocognitive, metabolic, and daytime functioning consequences. No drugs are
currently approved for OSA treatment.
This is a randomized, double blind, placebo controlled, cross-over, inpatient phase 2
clinical trial to examine the efficacy and the safety of a fixed dose level of AD128 in
patients with OSA.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Auxologico Italiano
Collaborators:
Apnimed Inc. STM Pharma PRO srl YGHEA, CRO Division of Ecol Studio spa